Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232

Reporter: J. Nicholas Lukens, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 5 de junio del 2011

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Nelarabine Plus Chemo Viable in Children With T-Cell ALL

Jul 2, 2012

Nelarabine well tolerated; encouraging for pediatric patients with slow early response in T-cell ALL

Pediatric High-Risk Leukemia Survival Has Improved Over Time

Jul 25, 2011

Improved AML/ALL outcomes following allogeneic, non-allogeneic hematopoietic cell transplantation

CT Scans Up Risk of Leukemia, Brain Tumors in Young

Jun 8, 2012

Relative risk from radiation increases risk about three-fold, although absolute risk is still small